-
Loading metrics
SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles
- Ting Zhang,
- Jianyan Xu,
- Junzhao Yin,
- Yun Gao,
- Hanwen Zheng,
- Beibei Fu,
- Jiakang Sun,
- Zhibin Xu,
- Shiwei Tu,
- Yuchang Mao,
- Weiyun Wen,
- Bolei Qu,
- Lingfeng You,
- Zhendong Xue,
- Xing Sun,
- Dan Cao,
- Jun Feng,
-
Min Hu ,
Roles Conceptualization, Supervision, Writing – review & editing
* E-mail: feng.he@hengrui.com (FH); min.hu@hengrui.com (MH)
Affiliation Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, China
⨯ - [ ... ],
- Feng He
- [ view all ]
- [ view less ]
https://orcid.org/0009-0003-1009-1233
SHR-A1811, a novel anti-HER2 antibody–drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles
- Ting Zhang,
- Jianyan Xu,
- Junzhao Yin,
- Yun Gao,
- Hanwen Zheng,
- Beibei Fu,
- Jiakang Sun,
- Zhibin Xu,
- Shiwei Tu,
- Yuchang Mao
x
- Published: June 26, 2025
- https://doi.org/10.1371/journal.pone.0326691